Theravance Biopharma Inc. (TBPH) shares plunged 28% in pre-market trading after the company announced that its hypertension drug failed to meet the primary endpoint in a pivotal late-stage clinical trial.

Theravance Biopharma Inc. (TBPH) shares plunged 28% in pre-market trading after the company announced that its hypertension drug failed to meet the primary endpoint in a pivotal late-stage clinical trial.

老虎证券2026/03/03 14:06

Show original

This disappointing trial result directly triggered a significant sell-off in the market. As the drug failed to achieve the preset efficacy endpoint, the company announced it would immediately conduct a comprehensive evaluation of the development project for this hypertension medication and plans to initiate a strategic review of the company’s overall pipeline. The purpose of this strategic assessment is to reallocate R&D resources and evaluate future development paths.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

Theravance Biopharma Inc. (TBPH) shares plunged 28% in pre-market trading after the company announced that its hypertension drug failed to meet the primary endpoint in a pivotal late-stage clinical trial.

You may also like

Trending news

Crypto prices